Idiotype-specific CD4+ T cells eradicate disseminated myeloma

Leukemia

Volumn 30, Issue 5, 2016, Pages 1216-1220

  Haabeth, O A ^a   Tveita, A ^a   Fauskanger, M ^a   Hennig, K ^a   Hofgaard, P O ^a   Bogen, B ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISSEMINATED CANCER; IMMUNE RESPONSE; LETTER; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR REJECTION; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA;

EID: 84946761882     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.278     Document Type: Letter

References (15)

1. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO et al. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express mhc class II molecules? Front Immunol 2014; 5: 174.
2. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371-383.
3. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 1994; 91: 5700-5704.
4. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syn-geneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 1986; 16: 1373-1378.
5. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res 2009; 69: 5901-5907.
6. Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows non-invasive spatiotemporal detection of osteolytic disease. PloS One 2012; 7: e51892.
7. Ghosh N, Gyory I, Wright G, Wood J, Wright KL. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J Biol Chem 2001; 276: 15264-15268.
8. Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT et al. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol 2007; 44: 2923-2932.
9. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-912.
10. Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M. Idiotype vaccines for human B-cell malignancies. Curr Pharma Des 2010; 16: 300-307.
11. Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Mcrobiol Immunol 2011; 344: 193-210.
12. McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P et al. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunol Immunother 2015; 64: 1021-1032.
13. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Rossmann ED, Rabbani H et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma-evaluation of T-cell responses by different readout systems. Haematologica 2007; 92: 110-114.
14. Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 2012; 170: 167-177.
15. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18: 1085-1092.